ERBB2 and glioblastoma: Therefore, to explore a more universal ACT for GBM patients, the Meenakshi group designed and validated trivalent CAR-T cells that simultaneously targeted HER2, IL13Rα2, and EphA2, which achieved nearly 100% clearance of GBM tumor cells.